Incorporating adherence into health economic modelling of osteoporosis
- 249 Downloads
Osteoporosis medications are seldom taken according to the recommendations of health-care providers. A theoretical model was constructed to investigate the variables of drug adherence that affect the cost-effectiveness of drugs, using osteoporosis treatment as a model. Important variables were the magnitude of drug effect, drug price, and fracture-related costs.
Adherence to anti-fracture medication is far from optimal and poses a challenge in osteoporosis management. The objectives of this study were to develop a model that could address adherence and identify the important drivers of cost-effectiveness.
An individual state transition model was constructed to compare two theoretical medications, one of which conferred optimal adherence and was 50% more costly. Adherence was divided into persistence and compliance. Partial compliance was assumed to be associated with a 20% loss of anti-fracture effect. Non-persistent patients had an offset time as long as their time on medication, to a maximum of 5 years.
The potentially important drivers of cost-effectiveness include reduced drug effectiveness due to poor compliance, offset time, fracture risk, anti-fracture drug effect, and drug price. Optimal adherence was associated with fewer osteoporotic fractures, and the impact was more evident among those with prior fractures. However, the health benefits of adherence were often partially offset by increased intervention costs associated with the improved drug-taking behaviour.
High adherence is likely to be associated with added value for health-care systems, but should be used with care as a central health economic argument.
KeywordsCompliance Cost-effectiveness Fracture Model Osteoporosis
We thank Enkhe Badamgarav and David Marcarios for their critical evaluation and helpful comments on the manuscript. Holly Zoog provided editorial support.
Conflicts of interest
Research for this manuscript was supported by Amgen Inc.
- 15.Jones ML, Wilkinson A (2006) Adverse effects and persistence with therapy in patients taking oral alendronate, etidronate or risedronate: systematic reviews (NICE). University of Sheffield, School of Health and Related Research (http://www.nice.org.uk/guidance/index.jsp?action=download&o=36718)
- 18.McCloskey E, De Takats D, Orgee J, Aropinn S et al (2005) Characteristics associated with non-persistence during daily therapy. Experience from the placebo wing of a community based clinical trial. J Bone Miner Res 20 [Suppl 1]:S282Google Scholar
- 26.Statistics Sweden. Swedens Statistical Databases. http://wwwscbse/eng/databaser/ssdasp
- 29.De Laet CE, van Hout BA, Burger H, Hofman A et al (1997) Bone density and risk of hip fracture in men and women: cross sectional analysis. Br Med J 315:221–225Google Scholar
- 30.Borgstrom F, Zethraeus N, Johnell O, Lidgren L et al (2005) Costs and quality of life associated with osteoporosis-related fractures in Sweden. Osteoporos Int 1–14Google Scholar
- 32.Zethraeus N, Strom O, Borgstrom F (2006) What is the risk of institutionalization after hip fracture? Osteoporosis Int 17 [Suppl 2] :S60Google Scholar
- 33.Stockholms stads budgetavräkning 2003. http://www.stockholm.se/files/71600-71699/file_71645.pdf. Accessed 20 December 2004
- 34.Ström O, Borgstrom F, Zethraeus N, Johnell O et al (2008) Long-term cost and effect on quality of life of osteoporosis-related fractures in Sweden. Acta Orthop (accepted)Google Scholar
- 42.IOF Cost-effectiveness reference model (http://www.iofbonehealth.org/health-professionals/health-economics/iof-cost-effectiveness-reference-model.html
- 44.Gujarati DN (1995) Basic econometrics. McGraw Hill, SingaporeGoogle Scholar
- 45.Kanis JA, Stevenson M, McCloskey EV, Davis S et al (2007) Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis. Health Technol Assess 11:1–256Google Scholar
- 46.Stevenson M, Davies S (2006) DSU economic evaluation of pooled alendronate and risedronate compared with strontium ranelate, raloxifene, etidronate and teriparatide. http://guidance.nice.org.uk/page.aspx?o=370643